A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis,” published in the November 2024 issue of Dermatology by Ferris et al.

One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

New data for investigational nipocalimab in Sjögren's Disease (SjD) and new research on the impact of TREMFYA® (guselkumab) in psoriatic arthritis (PsA) will be highlighted across three oral sessions ...

In this self-controlled, prospective trial sponsored by the manufacturer of the PDL, 22 patients with plaque psoriasis received four different treatment options, one each to one of four similar ...

Research shows lifestyle changes like diet, exercise, and smoking cessation can assist with improving psoriasis outcomes and ...

Psoriasis is a skin condition that involves an itchy, scaly rash. It is caused by the immune system attacking healthy cells, which speeds up skin cell growth and leads to a buildup of dead cells on ...

Plaque psoriasis is the most common type of psoriasis. Plaques are pink/red, raised, thick, inflamed skin patches covered by silvery-white scales. They typically have well-defined edges and may itch.

First-of-its-kind Phase 3b study shows TREMFYA ® achieved statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement ...

Guselkumab achieved clear or almost clear skin in 74.2% of patients with moderate plaque psoriasis, compared to 12.4% on placebo. The VISIBLE study showed rapid and significant clearance of scalp ...

moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment. Data from the Phase 3b SPECTREM study to measure skin clearance and other treatment outcomes in low ...

Skyrizi (risankizumab-rzaa) is a prescription drug that’s used to treat Crohn’s disease, plaque psoriasis, and psoriatic arthritis. Skyrizi can cause side effects that range from mild to serious.